Maria Coco is a Nephrology physician affiliated with Montefiore Medical Center. OpenAlex indexes 35 publications with 2,527 citations (h-index 18); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
111 E 210th St
Bronx, NY 104672401
Telephone
718-920-4136Registry record last updated 30 May 2013.
Clinical trials
- Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
Sponsor: Montefiore Medical Center
- Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients
Sponsor: Montefiore Medical Center
- The Use of ACE Inhibitors in the Early Renal Post-transplant Period
Sponsor: Montefiore Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
62.6%Calcium channel blocker18.3%Nifedipine Er63%Amlodipine Besylate37%Part D≥17 patientsLoop diuretic10.2%Furosemide100%Part D≥13 patients+ 8 more classes in this area
Metabolism & gastrointestinal
20%Vitamin D3 Analog11.2%Calcitriol100%Part D≥19 patientsSGLT2 inhibitor8.8%Jardiance64%Farxiga37%Part D<11 patientsOther
8.5%Potassium Binder5.4%Sodium Polystyrene Sulfonate100%Part D<11 patientsDrugs for treatment of hyperkalemia and hyperphosphatemia3.1%Lokelma100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effects of Three Months of Ergocalciferol Supplementation in Patients with Stages 3 and 4 CKD: Results from a Randomized Clinical Trial
Journal of the American Society of Nephrology
2023 - AKI in Hospitalized Patients with and without COVID-19: A Comparison Study
Journal of the American Society of Nephrology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Michelle Gong, MD
Montefiore Medical Center
Sheryl Haut, MD
Montefiore Medical Center
Andreas Kaubisch, MD
Montefiore Medical Center
Lewis Eisen, MD
Montefiore Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”